Growth Metrics

Adaptive Biotechnologies (ADPT) Cash & Current Investments (2018 - 2025)

Historic Cash & Current Investments for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $212.8 million.

  • Adaptive Biotechnologies' Cash & Current Investments fell 1255.91% to $212.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.8 million, marking a year-over-year decrease of 1255.91%. This contributed to the annual value of $222.3 million for FY2024, which is 3582.76% down from last year.
  • Adaptive Biotechnologies' Cash & Current Investments amounted to $212.8 million in Q3 2025, which was down 1255.91% from $197.9 million recorded in Q2 2025.
  • In the past 5 years, Adaptive Biotechnologies' Cash & Current Investments ranged from a high of $714.3 million in Q1 2021 and a low of $193.4 million during Q1 2025
  • Over the past 5 years, Adaptive Biotechnologies' median Cash & Current Investments value was $363.6 million (recorded in 2022), while the average stood at $372.6 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first plummeted by 5029.94% in 2021, then skyrocketed by 4110.76% in 2022.
  • Adaptive Biotechnologies' Cash & Current Investments (Quarter) stood at $353.1 million in 2021, then soared by 41.11% to $498.2 million in 2022, then crashed by 30.47% to $346.4 million in 2023, then crashed by 35.83% to $222.3 million in 2024, then dropped by 4.28% to $212.8 million in 2025.
  • Its Cash & Current Investments stands at $212.8 million for Q3 2025, versus $197.9 million for Q2 2025 and $193.4 million for Q1 2025.